WASHINGTON, July 14 (AFP) - A new, easily administered drug has cut in half the spread of AIDS from HIV infected mothers to their infants, the US National Institutes of Health (NIH) announced Wednesday.
According to the NIH, a single dose of antiretroviral nevirapine taken orally by the mother while in labor, followed by a dose for the baby three days after birth, reduced the transmission rate by half compared to a similar short course of AZT.
The development could halt the spread of AIDS to newborns in developing countries by some 300,00 to 400,000 babies a year, according to test results in Uganda.
"This study represents the most promising advance to date toward the goal of finding strategies that can be used worldwide to prevent the spread of HIV from infected mothers to their infants," National Institute of Allergies and Infectious Diseases director Anthony Fauci said.
AZT-based AIDS treatment proved to be too expensive and complicated for developing nations to use, where many mothers do not receive any pre-natal care.
Based on wholesale prices in the United States, the nevirapine treatment was 200 times cheaper than long-term AZT use, and 70 percent cheaper than short-term AZT treatment.
"This extraordinary finding is the most recent in our efforts to bring an end to AIDS, not only in the United States but in countries around the world," Health and Human Services Secretary Donna Shalala said.
According to the United Nations AIDS program in developing nations every day some 1,800 infants are born with the AIDS virus. In hardest-hit AIDS areas, almost 30 percent of pregnant women are infected with HIV and 25 to 35 percent of their infants are born infected.
Related Story: "Ugandan, US researchers in AIDS breakthrough study"
990714
AF990718
Copyright © AFP or Agence France-Presse, 1999 - AFP stories and photos shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, graphics or quoted in its texts. Further, that no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/